



Express Mail No. EV426923604US

Atty. Docket No: 0949-UTL-GP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/517,392

Confirmation No.: 5578

Inventors: Botti, Paolo

TC/A.U.: 1654

Filed: November 24, 2004

Examiner: Gudibande, S.R.

Title: CARBOXY PROTECTION STRATEGIES FOR  
ACIDIC C-TERMINAL AMINO ACIDS IN CHEMICAL  
LIGATION OF OLIGOPEPTIDES

TRANSMITTAL LETTER

MAILSTOP SEQUENCE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

- Amendment in Response to Notice Under 37 CFR §1.821-825 - 8 pgs
- Statement to Support Filing and Submission in Accordance with 37 CFR §1.821-1.825 (1pg)
- Paper Sequence Listing - 8 pgs
- Compact Disk Transmittal Letter Under 37 C.F.R. 1.52(e) – 1pg
- Copy of Notice to Comply – 1pg
- Two (2) compact discs in computer-readable format (CRF), labeled "Sequence Listing-Copy 1" and "Sequence Listing-Copy 2."
- Return Post Card

The Patent Office is authorized to debit any underpayment or credit any overpayment during the pendency of this application to Deposit Account No. 010535.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: October 30, 2007

By: Richard San Pietro  
Richard San Pietro  
Registration No. 45,071

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. 1.10

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service for "Express Mail Post Office to Addressee" service, Express Mail Label No. EV426923604US in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

October 30, 2007  
Date of Deposit

Marutzella Castro  
Marutzella Castro



Express Mail No. EV426923604US

Atty. Docket No. 0949-UTL-GP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appl. Serial No.:** 10/517,392

**Confirmation No.:** 5578

**Inventors:** Botti, Paolo

**TC/A.U.:** 1654

**Filed:** November 24, 2004

**Examiner:** Gudibande, S.R.

**Title:** CARBOXY PROTECTION STRATEGIES  
FOR ACIDIC C-TERMINAL AMINO ACIDS IN  
CHEMICAL LIGATION OF OLIGOPEPTIDES

**COMPACT DISK TRANSMITTAL LETTER UNDER 37 C.F.R. 1.52(e)**

MAILSTOP SEQUENCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In accordance with 37 C.F.R.1.52(e), Applicants herewith transmit the "Sequence Listing for the above-referenced application on two identical compact discs labeled "Sequence Listing-Copy 1" and Sequence Listing-Copy 2." The information contained on each disk is as follows:

Machine Format:	IBM-PC
Operating System Compatibility:	MS-Windows
File Name:	<b>0949-UTL-GP.txt</b>
File Size:	7 KB
Date File Created:	October 30, 2007

In accordance with 37 C.F.R. 152(e)(4), I hereby state that the contents of the two compact discs are identical.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: October 30, 2007

By:   
Richard San Pietro  
Registration No. 45,071

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936



**UNITED STATES PATENT AND TRADEMARK OFFICE**


UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/517,392	FIRST NAMED APPLICANT Paolo Botti	ATTY. DOCKET NO. 021724-000410US
		INTERNATIONAL APPLICATION NO. PCT/IB03/05473
		I.A. FILING DATE 06/09/2003
		PRIORITY DATE 06/10/2002

44638  
 Intellectual Property Department  
 Amylin Pharmaceuticals, Inc.  
 9360 Towne Centre Drive  
 San Diego, CA 92121

**CONFIRMATION NO. 5578**

**371 FORMALITIES LETTER**



\*OC000000025618950\*

Date Mailed: 08/30/2007

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/517,392	PCT/IB03/05473	021724-000410US

FORM PCT/DO/EO/922 (371 Formalities Notice)